Your browser is no longer supported. Please, upgrade your browser.
Brickell Biotech, Inc.
Index- P/E- EPS (ttm)-1.03 Insider Own1.20% Shs Outstand66.93M Perf Week-0.48%
Market Cap58.31M Forward P/E- EPS next Y-0.38 Insider Trans24.25% Shs Float65.67M Perf Month2.22%
Income-25.80M PEG- EPS next Q-0.12 Inst Own12.10% Short Float6.19% Perf Quarter-26.98%
Sales0.80M P/S72.89 EPS this Y81.00% Inst Trans-0.54% Short Ratio3.11 Perf Half Y26.35%
Book/sh0.48 P/B1.81 EPS next Y24.00% ROA-81.70% Target Price- Perf Year-31.04%
Cash/sh- P/C- EPS next 5Y- ROE-108.80% 52W Range0.47 - 2.61 Perf YTD11.33%
Dividend- P/FCF- EPS past 5Y34.40% ROI-76.30% 52W High-66.71% Beta0.17
Dividend %- Quick Ratio4.10 Sales past 5Y-38.60% Gross Margin- 52W Low86.46% ATR0.05
Employees13 Current Ratio4.10 Sales Q/Q-96.00% Oper. Margin- RSI (14)47.14 Volatility3.55% 5.55%
OptionableNo Debt/Eq0.01 EPS Q/Q67.30% Profit Margin- Rel Volume0.70 Prev Close0.90
ShortableYes LT Debt/Eq0.01 EarningsMay 13 AMC Payout- Avg Volume1.31M Price0.87
Recom1.50 SMA201.42% SMA50-5.63% SMA200-6.53% Volume952,942 Change-3.08%
Aug-28-20Initiated Lake Street Buy $6
Aug-25-20Initiated Oppenheimer Outperform $5
Jun-01-21 08:00AM  
May-13-21 04:01PM  
May-06-21 03:00PM  
Apr-29-21 08:00AM  
Apr-27-21 07:30AM  
Apr-23-21 10:01AM  
Apr-16-21 10:00AM  
Apr-15-21 08:00AM  
Mar-09-21 04:01PM  
Mar-05-21 08:00AM  
Mar-02-21 12:30PM  
Feb-25-21 04:05PM  
Feb-23-21 04:01PM  
Jan-19-21 07:00AM  
Jan-06-21 12:50AM  
Dec-07-20 07:30AM  
Nov-18-20 07:00AM  
Nov-16-20 08:00AM  
Nov-12-20 04:01PM  
Oct-29-20 08:00AM  
Oct-22-20 08:00PM  
Sep-29-20 10:30AM  
Sep-25-20 07:00AM  
Sep-10-20 04:05PM  
Sep-08-20 07:30AM  
Aug-31-20 04:05PM  
Aug-12-20 04:01PM  
Aug-03-20 04:05PM  
Jun-17-20 10:00PM  
Jun-15-20 06:30AM  
May-31-20 08:04AM  
May-13-20 04:01PM  
May-04-20 04:05PM  
Mar-18-20 04:01PM  
Mar-09-20 04:05PM  
Mar-04-20 06:30AM  
Feb-20-20 11:43AM  
Feb-18-20 06:30AM  
Jan-10-20 04:05PM  
Nov-13-19 04:05PM  
Oct-30-19 04:42PM  
Sep-03-19 06:45AM  
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Chadha DeepakChief Research & Dev. OfficerMay 19Buy0.8312,50010,37878,167May 19 05:01 PM
Chadha DeepakChief Research & Dev. OfficerMay 18Buy0.822,7002,21265,667May 19 05:01 PM
Sklawer Andrew DCOO and SecretaryMay 17Buy0.8015,37512,300124,625May 19 05:03 PM
McAvoy David R.General Counsel and CCOMay 17Buy0.807,9806,38413,980May 19 05:02 PM
McAvoy David R.General Counsel and CCOMay 17Buy0.8018,62214,898110,755May 19 05:02 PM
Brown Robert BusardChief Executive OfficerMar 15Buy1.18100,000117,780186,957Mar 17 04:21 PM
McAvoy David R.General Counsel and CCOSep 18Buy0.846,0005,0396,000Sep 21 04:19 PM
McAvoy David R.General Counsel and CCOSep 18Buy0.8316,52613,71375,883Sep 21 04:19 PM
VERU DENNISON TDirectorSep 16Buy0.8014,64511,75850,810Sep 17 05:07 PM
VERU DENNISON TDirectorSep 15Buy0.8115,35512,41636,165Sep 17 05:07 PM